KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $47.1 million.

  • BeOne Medicines' Non-Current Deferred Tax Liability rose 19536.24% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year increase of 19536.24%. This contributed to the annual value of $42.0 million for FY2024, which is 10889.65% up from last year.
  • BeOne Medicines' Non-Current Deferred Tax Liability amounted to $47.1 million in Q3 2025, which was up 19536.24% from $44.1 million recorded in Q2 2025.
  • BeOne Medicines' Non-Current Deferred Tax Liability's 5-year high stood at $47.1 million during Q3 2025, with a 5-year trough of $10.8 million in Q1 2021.
  • Over the past 5 years, BeOne Medicines' median Non-Current Deferred Tax Liability value was $15.9 million (recorded in 2024), while the average stood at $21.7 million.
  • In the last 5 years, BeOne Medicines' Non-Current Deferred Tax Liability tumbled by 1818.29% in 2023 and then surged by 19536.24% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Non-Current Deferred Tax Liability stood at $14.2 million in 2021, then skyrocketed by 73.46% to $24.6 million in 2022, then decreased by 18.18% to $20.1 million in 2023, then surged by 108.9% to $42.0 million in 2024, then grew by 12.04% to $47.1 million in 2025.
  • Its last three reported values are $47.1 million in Q3 2025, $44.1 million for Q2 2025, and $43.1 million during Q1 2025.